Patents by Inventor Susan J. Kelly
Susan J. Kelly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180223263Abstract: A naturally occurring or recombinant protein, especially a mutein of porcine urate oxidase (uricase), that is essentially free of large aggregates can be rendered substantially non-immunogenic by conjugation with a sufficiently small number of strands of polymer such that the bioactivity of the protein is essentially retained in the conjugate. Such conjugates are unusually well suited for treatment of chronic conditions because they are less likely to induce the formation of antibodies and/or accelerated clearance than are similar conjugates prepared from protein preparations containing traces of large aggregates.Type: ApplicationFiled: August 17, 2017Publication date: August 9, 2018Applicants: HORIZON PHARMA RHEUMATOLOGY LLC, DUKE UNIVERSITYInventors: Merry R. Sherman, Mark G. P Saifer, L. David Williams, Michael S. Hershfield, Susan J. Kelly
-
Patent number: 9885024Abstract: A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.Type: GrantFiled: July 22, 2015Date of Patent: February 6, 2018Assignees: DUKE UNIVERSITY, HORIZON PHARMA RHEUMATOLOGY LLCInventors: L. David Williams, Michael S. Hershfield, Susan J. Kelly, Mark G. P. Saifer, Merry R. Sherman
-
Publication number: 20160160188Abstract: A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.Type: ApplicationFiled: July 22, 2015Publication date: June 9, 2016Applicants: Duke University, Crealta Pharmaceuticals LLCInventors: L. David WILLIAMS, Michael S. Hershfield, Susan J. Kelly, Mark G.P. Saifer, Merry R. Sherman
-
Patent number: 8921064Abstract: A naturally occurring or recombinant protein, especially a mutein of porcine urate oxidase (uricase), that is essentially free of large aggregates can be rendered substantially non-immunogenic by conjugation with a sufficiently small number of strands of polymer such that the bioactivity of the protein is essentially retained in the conjugate. Such conjugates are unusually well suited for treatment of chronic conditions because they are less likely to induce the formation of antibodies and/or accelerated clearance than are similar conjugates prepared from protein preparations containing traces of large aggregates.Type: GrantFiled: April 13, 2011Date of Patent: December 30, 2014Assignees: Mountain View Pharmaceuticals, Inc., Duke UniversityInventors: Merry R. Sherman, Mark G. P. Saifer, L. David Williams, Michael S. Hershfield, Susan J. Kelly
-
Publication number: 20140363414Abstract: A naturally occurring or recombinant protein, especially a mutein of porcine urate oxidase (uricase), that is essentially free of large aggregates can be rendered substantially non-immunogenic by conjugation with a sufficiently small number of strands of polymer such that the bioactivity of the protein is essentially retained in the conjugate. Such conjugates are unusually well suited for treatment of chronic conditions because they are less likely to induce the formation of antibodies and/or accelerated clearance than are similar conjugates prepared from protein preparations containing traces of large aggregates.Type: ApplicationFiled: August 18, 2014Publication date: December 11, 2014Applicants: Mountain View Pharmaceuticals, Inc., Duke UniversityInventors: Merry R. SHERMAN, Mark G.P. Saifer, L. David Williams, Michael S. Hershfield, Susan J. Kelly
-
Patent number: 8618267Abstract: A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.Type: GrantFiled: April 8, 2011Date of Patent: December 31, 2013Assignees: Mountain View Pharmaceuticals, Inc., Duke UniversityInventors: L. David Williams, Michael S. Hershfield, Susan J. Kelly, Mark G. P. Saifer, Merry R. Sherman
-
Publication number: 20130052677Abstract: A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.Type: ApplicationFiled: April 8, 2011Publication date: February 28, 2013Inventors: L. David WILLIAMS, Michael S. Hershfield, Susan J. Kelly, Mark G.P. Saifer, Merry R. Sherman
-
Publication number: 20120149083Abstract: A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.Type: ApplicationFiled: November 29, 2011Publication date: June 14, 2012Applicants: Duke University, Mountain View Pharmaceuticals, Inc.Inventors: L. David Williams, Michael S. Hershfield, Susan J. Kelly, Mark G.P. Saifer, Merry R. Sherman
-
Patent number: 8067553Abstract: A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.Type: GrantFiled: April 28, 2010Date of Patent: November 29, 2011Assignees: Mountain View Pharmaceuticals, Inc., Duke UniversityInventors: L. David Williams, Michael S. Hershfield, Susan J. Kelly, Mark G. P. Saifer, Merry R. Sherman
-
Publication number: 20110287466Abstract: A naturally occurring or recombinant protein, especially a mutein of porcine urate oxidase (uricase), that is essentially free of large aggregates can be rendered substantially non-immunogenic by conjugation with a sufficiently small number of strands of polymer such that the bioactivity of the protein is essentially retained in the conjugate. Such conjugates are unusually well suited for treatment of chronic conditions because they are less likely to induce the formation of antibodies and/or accelerated clearance than are similar conjugates prepared from protein preparations containing traces of large aggregates.Type: ApplicationFiled: April 13, 2011Publication date: November 24, 2011Inventors: Merry R. Sherman, Mark G.P. Saifer, L. David Williams, Michael S. Hershfield, Susan J. Kelly
-
Patent number: 7927852Abstract: A naturally occurring or recombinant protein, especially a mutein of porcine urate oxidase (uricase), that is essentially free of large aggregates can be rendered substantially non-immunogenic by conjugation with a sufficiently small number of strands of polymer such that the bioactivity of the protein is essentially retained in the conjugate. Such conjugates are unusually well suited for treatment of chronic conditions because they are less likely to induce the formation of antibodies and/or accelerated clearance than are similar conjugates prepared from protein preparations containing traces of large aggregates.Type: GrantFiled: August 3, 2007Date of Patent: April 19, 2011Assignee: Mountain View Pharmaceuticals, Inc.Inventors: Merry R. Sherman, Mark G. P. Saifer, L. David Williams, Michael S. Hershfield, Susan J. Kelly
-
Patent number: 7927589Abstract: A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.Type: GrantFiled: August 3, 2007Date of Patent: April 19, 2011Assignee: Mountain View Pharmaceuticals, Inc.Inventors: L. David Williams, Michael S. Hershfield, Susan J. Kelly, Mark G. P. Saifer, Merry R. Sherman
-
Publication number: 20100323422Abstract: A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.Type: ApplicationFiled: April 28, 2010Publication date: December 23, 2010Inventors: L. David WILLIAMS, Michael S. Hershfield, Susan J. Kelly, Mark G. P. Saifer, Merry R. Sherman
-
Publication number: 20100323423Abstract: A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.Type: ApplicationFiled: April 28, 2010Publication date: December 23, 2010Inventors: L. David WILLIAMS, Michael S. Herschfield, Susan J. Kelly, Mark G.P. Saifer, Merry R. Sherman
-
Patent number: 7723089Abstract: A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.Type: GrantFiled: April 19, 2001Date of Patent: May 25, 2010Assignees: Mountain View Pharmaceuticals, Inc., Duke UniversityInventors: L. David Williams, Michael S. Hershfield, Susan J. Kelly, Mark G. P. Saifer, Merry R. Sherman
-
Patent number: 7056713Abstract: The present invention relates, in general, to urate oxidase (uricase) proteins and nucleic acid molecules encoding same. In particular, the invention relates to uricase proteins which are particularly useful as, for example, intermediates for making improved modified uricase proteins with reduced immunogenicity and increased bioavailability.Type: GrantFiled: August 5, 1999Date of Patent: June 6, 2006Assignee: Duke UniversityInventors: Michael Hershfield, Susan J. Kelly
-
Publication number: 20030166249Abstract: A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.Type: ApplicationFiled: April 19, 2001Publication date: September 4, 2003Inventors: L. David Williams, Michael S. Hershfield, Susan J. Kelly, Mark G. P. Saifer, Merry R. Sherman
-
Patent number: 6576235Abstract: A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.Type: GrantFiled: August 6, 1999Date of Patent: June 10, 2003Assignees: Mountain View Pharmaceuticals, Inc., Duke UniversityInventors: L. David Williams, Michael S. Hershfield, Susan J. Kelly, Mark G. P. Saifer, Merry R. Sherman
-
Patent number: 4041111Abstract: Synthesis of phosphonate monoesters, as well as the use of such monoesters as substrates for enzymes which normally hydrolyze phosphodiester linkages, and a method for distinguishing between Type I and Type II phosphodiesterase enzymes using such monoesters as substrates are disclosed herein. Monoesters of phosphonic acids are prepared by the displacement of chloride from an appropriate phosphonic acid dichloride by a phenol or alcohol with pyridine as the solvent, reacting the same and then removing the solvent, after which the remaining ester chloride and dichloride are hydrolyzed by addition of water. The acid and ester are then separated and the acid-free ester is taken up in a polar organic solvent and precipitated as a salt by the addition of aqueous base, with the product then being filtered, washed with fresh acetone, dried and then stored until needed.Type: GrantFiled: March 4, 1975Date of Patent: August 9, 1977Assignee: Purdue Research FoundationInventors: Susan J. Kelly, Larry G. Butler